PDCD1 and neoplasm: Instead, our data suggest that patients with higher expression levels of inhibitory receptors (particularly PD-1) in their CAR-T cell infusion products are more susceptible to immune inhibition within the tumor microenvironment, thus would be strong candidates for combination therapy with checkpoint inhibitions to drive a stronger overall clinical response (5).